Organ Tissue Engineering is a multidisciplinary field that combines principles of engineering, biology, and medicine to develop artificial organs or tissues for transplantation. The goal is to create functional substitutes capable of restoring or improving the normal physiological functions of damaged or diseased organs. This innovative approach addresses the shortage of donor organs for transplantation and aims to overcome issues like organ rejection. The process of organ tissue engineering involves utilizing scaffolds, cells, and signaling molecules. Scaffolds act as the structural framework, providing a three-dimensional environment for cell attachment and growth. Cells, often sourced from the patient or other compatible donors, are seeded onto the scaffolds. These cells can be stem cells, which possess the ability to differentiate into various cell types. Signaling molecules, such as growth factors, guide cell behavior and tissue development. Researchers explore various techniques, including 3D bioprinting, to precisely arrange cells and biomaterials, mimicking the architecture of native tissues. Decellularization, a process where cells are removed from donor organs, leaving behind the extracellular matrix, is another strategy used to create biological scaffolds for tissue engineering. Advances in organ tissue engineering have been seen in the development of functional tissues like skin, blood vessels, and cartilage. However, engineering complex organs such as the heart or liver presents significant challenges due to their intricate structure and function. Overcoming these challenges requires a deep understanding of the biology of the targeted organ and the development of sophisticated techniques to recreate its complexity. Ethical considerations, regulatory challenges, and the need for long-term functionality remain important aspects in the field of organ tissue engineering. Despite the ongoing research, the ultimate goal is to provide viable solutions for patients suffering from organ failure, offering alternatives to traditional transplantation and significantly impacting the future of medicine.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy